Shares of Ipca Laboratories surged 4.72% to Rs 1,423.20 in Friday's session, driven by high volume. The stock is among the top gainers on the Nifty Midcap 150 index.
Quarterly Financial Performance:
The consolidated quarterly financial performance of Ipca Laboratories shows consistent revenue growth. Here's a summary:
| Heading | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|
| Revenue | Rs 2,092.63 Crore | Rs 2,354.90 Crore | Rs 2,245.37 Crore | Rs 2,246.69 Crore | Rs 2,308.85 Crore |
| Net Profit | Rs 198.98 Crore | Rs 245.44 Crore | Rs 277.33 Crore | Rs 65.78 Crore | Rs 234.42 Crore |
| EPS | 7.58 | 9.05 | 9.78 | 2.67 | 9.19 |
Annual Financial Performance:
The consolidated annual financial performance demonstrates steady growth over the years.
| Heading | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | Rs 5,419.99 Crore | Rs 5,829.79 Crore | Rs 6,244.32 Crore | Rs 7,705.04 Crore | Rs 8,939.59 Crore |
| Net Profit | Rs 1,148.84 Crore | Rs 910.95 Crore | Rs 491.93 Crore | Rs 529.21 Crore | Rs 787.53 Crore |
| EPS | 45.01 | 34.85 | 18.58 | 25.82 | 35.14 |
| BVPS | 371.79 | 219.51 | 233.16 | 304.57 | 273.88 |
| ROE | 24.24 | 16.09 | 8.06 | 8.64 | 10.61 |
| Debt to Equity | 0.05 | 0.14 | 0.25 | 0.22 | 0.19 |
Annual Income Statement:
The annual income statement provides further insights into Ipca Laboratories' financial health.
| Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | |
|---|---|---|---|---|---|
| Sales | Rs 8,939 Crore | Rs 7,705 Crore | Rs 6,244 Crore | Rs 5,829 Crore | Rs 5,419 Crore |
| Other Income | Rs 92 Crore | Rs 124 Crore | Rs 125 Crore | Rs 66 Crore | Rs 62 Crore |
| Total Income | Rs 9,032 Crore | Rs 7,829 Crore | Rs 6,369 Crore | Rs 5,896 Crore | Rs 5,482 Crore |
| Total Expenditure | Rs 7,816 Crore | Rs 6,848 Crore | Rs 5,579 Crore | Rs 4,752 Crore | Rs 4,084 Crore |
| EBIT | Rs 1,216 Crore | Rs 980 Crore | Rs 790 Crore | Rs 1,143 Crore | Rs 1,398 Crore |
| Interest | Rs 84 Crore | Rs 138 Crore | Rs 45 Crore | Rs 7 Crore | Rs 9 Crore |
| Tax | Rs 343 Crore | Rs 313 Crore | Rs 253 Crore | Rs 224 Crore | Rs 240 Crore |
| Net Profit | Rs 787 Crore | Rs 529 Crore | Rs 491 Crore | Rs 910 Crore | Rs 1,148 Crore |
The quarterly income statement for Ipca Laboratories.
| Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | |
|---|---|---|---|---|---|
| Sales | Rs 2,308 Crore | Rs 2,246 Crore | Rs 2,245 Crore | Rs 2,354 Crore | Rs 2,092 Crore |
| Other Income | Rs 32 Crore | Rs 25 Crore | Rs 20 Crore | Rs 26 Crore | Rs 20 Crore |
| Total Income | Rs 2,341 Crore | Rs 2,272 Crore | Rs 2,265 Crore | Rs 2,381 Crore | Rs 2,113 Crore |
| Total Expenditure | Rs 1,992 Crore | Rs 2,123 Crore | Rs 1,880 Crore | Rs 2,013 Crore | Rs 1,798 Crore |
| EBIT | Rs 349 Crore | Rs 149 Crore | Rs 384 Crore | Rs 367 Crore | Rs 314 Crore |
| Interest | Rs 18 Crore | Rs 21 Crore | Rs 16 Crore | Rs 22 Crore | Rs 24 Crore |
| Tax | Rs 96 Crore | Rs 62 Crore | Rs 90 Crore | Rs 99 Crore | Rs 91 Crore |
| Net Profit | Rs 234 Crore | Rs 65 Crore | Rs 277 Crore | Rs 245 Crore | Rs 198 Crore |
The cash flow statement provides details on the company's cash inflows and outflows.
| Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | |
|---|---|---|---|---|---|
| Operating Activities | Rs 1,321 Crore | Rs 944 Crore | Rs 805 Crore | Rs 856 Crore | Rs 1,090 Crore |
| Investing Activities | Rs -869 Crore | Rs -1,291 Crore | Rs -725 Crore | Rs -855 Crore | Rs -520 Crore |
| Financing Activities | Rs -282 Crore | Rs -552 Crore | Rs 507 Crore | Rs 426 Crore | Rs -305 Crore |
| Others | Rs 0 Crore | Rs 76 Crore | Rs 0 Crore | Rs 4 Crore | Rs 0 Crore |
| Net Cash Flow | Rs 168 Crore | Rs -823 Crore | Rs 588 Crore | Rs 431 Crore | Rs 263 Crore |
The balance sheet details the company's assets, liabilities, and equity.
| Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | |
|---|---|---|---|---|---|
| Share Capital | Rs 25 Crore | Rs 25 Crore | Rs 25 Crore | Rs 25 Crore | Rs 25 Crore |
| Reserves & Surplus | Rs 6,923 Crore | Rs 6,306 Crore | Rs 5,816 Crore | Rs 5,466 Crore | Rs 4,676 Crore |
| Current Liabilities | Rs 2,386 Crore | Rs 2,355 Crore | Rs 1,805 Crore | Rs 1,465 Crore | Rs 1,160 Crore |
| Other Liabilities | Rs 2,425 Crore | Rs 2,413 Crore | Rs 978 Crore | Rs 681 Crore | Rs 206 Crore |
| Total Liabilities | Rs 11,760 Crore | Rs 11,101 Crore | Rs 8,626 Crore | Rs 7,638 Crore | Rs 6,068 Crore |
| Fixed Assets | Rs 4,798 Crore | Rs 4,805 Crore | Rs 2,853 Crore | Rs 2,669 Crore | Rs 2,260 Crore |
| Current Assets | Rs 6,268 Crore | Rs 5,538 Crore | Rs 5,189 Crore | Rs 4,457 Crore | Rs 3,436 Crore |
| Other Assets | Rs 694 Crore | Rs 756 Crore | Rs 583 Crore | Rs 511 Crore | Rs 370 Crore |
| Total Assets | Rs 11,760 Crore | Rs 11,101 Crore | Rs 8,626 Crore | Rs 7,638 Crore | Rs 6,068 Crore |
| Contingent Liabilities | Rs 613 Crore | Rs 303 Crore | Rs 2,125 Crore | Rs 274 Crore | Rs 369 Crore |
Key financial ratios for Ipca Laboratories.
| Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | |
|---|---|---|---|---|---|
| Basic EPS (Rs.) | 35.14 | 25.82 | 18.58 | 34.85 | 45.01 |
| Diluted Eps (Rs.) | 29.08 | 21.57 | 18.58 | 34.85 | 45.01 |
| Book Value /Share (Rs.) | 273.88 | 304.57 | 233.16 | 219.51 | 371.79 |
| Dividend/Share (Rs.) | 4.00 | 4.00 | 4.00 | 4.00 | 8.00 |
| Face Value | 1 | 1 | 1 | 1 | 2 |
| Gross Profit Margin (%) | 20.34 | 18.76 | 16.85 | 23.59 | 29.65 |
| Operating Margin (%) | 15.89 | 14.12 | 12.66 | 19.61 | 25.79 |
| Net Profit Margin (%) | 8.80 | 6.86 | 7.87 | 15.62 | 21.19 |
| Return on Networth / Equity (%) | 10.61 | 8.64 | 8.06 | 16.09 | 24.24 |
| ROCE (%) | 15.15 | 12.44 | 11.59 | 18.52 | 28.48 |
| Return On Assets (%) | 6.27 | 4.93 | 5.46 | 11.57 | 18.78 |
| Current Ratio (X) | 2.63 | 2.35 | 2.87 | 3.04 | 2.96 |
| Quick Ratio (X) | 1.55 | 1.30 | 1.91 | 1.77 | 1.59 |
| Debt to Equity (x) | 0.19 | 0.22 | 0.25 | 0.14 | 0.05 |
| Interest Coverage Ratios (X) | 21.42 | 10.46 | 23.11 | 178.91 | 177.79 |
| Asset Turnover Ratio (%) | 0.78 | 0.78 | 0.77 | 0.80 | 0.91 |
| Inventory Turnover Ratio (X) | 3.55 | 1.05 | 0.95 | 0.96 | 1.10 |
| 3 Yr CAGR Sales (%) | 23.83 | 19.23 | 15.90 | 24.30 | 28.99 |
| 3 Yr CAGR Net Profit (%) | -7.02 | -32.13 | -10.30 | 43.23 | 117.14 |
| P/E (x) | 42.74 | 47.92 | 43.61 | 30.58 | 21.15 |
| P/B (x) | 5.48 | 4.96 | 3.52 | 4.90 | 5.13 |
| EV/EBITDA (x) | 22.26 | 23.45 | 19.23 | 19.73 | 14.96 |
| P/S (x) | 4.26 | 4.08 | 3.29 | 4.62 | 4.45 |
Ipca Laboratories has a history of corporate actions, including dividends and stock splits.
Dividends:
The company has consistently distributed dividends to its shareholders.
A bonus issue was announced on October 27, 2004, with a ratio of 1:1 and an ex-bonus date of January 28, 2005.
Stock Splits:
Ipca Laboratories has split its stock on two occasions:
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
